ArticleChemical biology & drug design2026
Design, Optimization and Mechanistic Insights Into Terpenoid-Derived Inhibitors of Protein Kinase C Iota.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Protein kinase C iota (PKCι) is an atypical PKC isoform overexpressed in several human cancers and associated with tumor initiation, maintenance, and resistance to therapy. Meroxest, a synthetic naphthoquinone merosesquiterpene previously shown to exert antitumor activity in breast cancer models, has an incompletely defined mechanism of action. Here, we profiled meroxest against a 410-kinase panel and synthesized a focused set of analogues to obtain preliminary PKCι-oriented structure-activity information. At 10 μM, meroxest reduced PKCι enzymatic activity to 52% of control and Cdc7/cyclin B1 activity to 63%, identifying PKCι as the most inhibited kinase in the panel while also indicating that additional kinase targets may contribute to the biological activity of this scaffold. Docking studies supported a plausible interaction of meroxest within the PKCι catalytic site, including hydrogen-bond contacts with Gly398 and Phe423 consistent with an ATP-competitive binding mode. Biochemical evaluation of a focused library against PKCι at 10 μM showed that preservation of the quinone framework was important for activity, whereas most structural modifications produced only limited changes under the assay conditions used. Compound 19, lacking the methyl substituent on the naphthoquinone ring, showed a modest improvement relative to meroxest. Overall, these results support PKCι as a leading candidate target emerging from the meroxest kinase profile and identify compound 19 as a scaffold for further optimization. Future studies will focus on further optimization to improve the modest PKCι inhibitory potency, evaluate activity against Cdc7/cyclin B1 beyond the parent compound, and validate target engagement in cell-based assays, aiming to identify optimal candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.